Alkem Laboratories acquires 79,36,50,794 shares of Alkem Medtech via rights issue
Alkem Laboratories · Pharmaceuticals & Biotechnology
Key highlights
- Acquired 79,36,50,794 equity shares at issue price of Rs. 13.86 per share, allotted by Alkem Medtech on 15th July, 2026
- Cash consideration; cost of acquisition stated as Rs. 11,00,00,00,005/- for the rights shares
- Alkem Medtech, a wholly owned subsidiary, had turnover of INR 15.13 crores for FY ended 31st March, 2026, in medical devices
Why it's rated notable: amount is ₹500 crore or more
Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.
Original filing
Announcement under Regulation 30 (LODR)-Acquisition
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Alkem Laboratories
- Acquisition / mergerNotableAlkem Laboratories completes acquisition of majority stake in Occlutech Holding AG
- Acquisition / mergerNotableAlkem Laboratories updates acquisition agreement for Occlutech Holding AG
- Fundraise / allotmentNotableAlkem Laboratories receives land allotment for new manufacturing facility in Ujjain
Other acquisition / merger filings this fortnight
- IndiGrid Infrastructure Trust Q2 FY27 Earnings Conference Call Transcript Released
- Cubical Financial Services Ltd announces promoter reclassification post open offer
- Novus Loyalty Limited approves acquisition of AutoPe Payment Solutions via share swap
- Shish Industries Limited files Composite Scheme of Amalgamation proposal
- Jubilant Ingrevia Limited updates on acquisition of 40% stake in Zettaone Technologies
- NHC Foods approves quarter results, 99.98% Sachmaas Foods investment, two appointments
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.